Brainstorm Cell Therapeutics (BCLI) Projected to Post Quarterly Earnings on Monday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is expected to announce its Q3 2026 resultson Monday, November 16th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Friday, August 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.06). On average, analysts expect Brainstorm Cell Therapeutics to post ($3.01) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.

Brainstorm Cell Therapeutics Stock Performance

Shares of Brainstorm Cell Therapeutics stock opened at $0.90 on Monday. Brainstorm Cell Therapeutics has a 1 year low of $0.46 and a 1 year high of $1.69. The company’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $0.84. The company has a market cap of $12.83 million, a price-to-earnings ratio of -0.27 and a beta of 0.35.

About Brainstorm Cell Therapeutics

BrainStorm Cell Therapeutics Inc is a biotechnology company focused on developing cell-based therapies for neurodegenerative diseases. The company’s technology platform uses autologous mesenchymal stem cells, derived from a patient’s bone marrow and induced to produce neurotrophic factors that may support nerve-cell survival and repair.

Its lead product candidate, NurOwn, also known as debamestrocel or MSC-NTF cells, is being developed primarily for amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis.